Current Psychiatry Reports

, 15:387 | Cite as

Immunity, Inflammation, and Bipolar Disorder: Diagnostic and Therapeutic Implications

  • Nora HamdaniEmail author
  • Raphael Doukhan
  • Ozlem Kurtlucan
  • Ryad Tamouza
  • Marion Leboyer
Bipolar Disorders (WH Coryell, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Bipolar Disorders


Bipolar disorder is now known to be associated not only with highly prevalent co-occurring psychiatric and substance use disorders but also with medical comorbidities, such as cardiovascular diseases, diabetes mellitus, obesity and thyroid dysfunction. Inflammatory disturbances repeatedly observed in bipolar disorder, can explain some of the comorbidity between bipolar disorder and medical disorder. This revised perspective of bipolar disorders should promote the development of therapeutic tools. Immuno-inflammatory dysfunction may well represent a significant component of the underlying pathophysiology of the disorder. We therefore propose to review the immuno-inflammatory hypothesis in bipolar disorder considering the co-occurence with autoimmune diseases, immunological and inflammatory markers, as well as immuno-genetic markers which could lead to personalized treatments.


Bipolar disorder CRP Cytokines Auto-antibody Immuno-genetic Endogenous retroviruses Comorbid substance use disorder Medical comorbidity Psychiatry 



This work was supported by INSERM (UMRS 940 and U955), assistante Publique des Hôpitaux de Paris, Agence Nationale de la Recherche (programmeANR-MNP2008 - VIP project) and fondaMental foundation.

Compliance with Ethics Guideline

Conflict of Interest

Nora Hamdani, Raphael Doukhan, Ozlem Kurtlucan, Ryad Tamouza, and Marion Leboyer declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Recently published papers on the latest scientific advances on immunoinflammation in bipolar disorders have been highlighted as:• Of importance

  1. 1.
    Bauer MS, Altshuler L, Evans DR, et al. Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. J Affect Disord. 2005;85:301–15.PubMedCrossRefGoogle Scholar
  2. 2.
    • Leboyer M, Kupfer DJ. Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry. 2010;71(12):1689–95. An original paper with useful advices.PubMedCrossRefGoogle Scholar
  3. 3.
    • Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 2012;141(1):1–10. A good review of comorbid diseases in bipolar disorder.PubMedCrossRefGoogle Scholar
  4. 4.
    Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Kupfer DJ. The increasing medical burden in medical disorder. JAMA. 2005;20:2528–30.CrossRefGoogle Scholar
  6. 6.
    Goldstein BI, Kem DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008;10:788–97.PubMedCrossRefGoogle Scholar
  8. 8.
    Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147–56.PubMedCrossRefGoogle Scholar
  9. 9.
    Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23(1):40–7.PubMedGoogle Scholar
  11. 11.
    Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S–60S.PubMedGoogle Scholar
  12. 12.
    Laaksonen D, Lakka HM, Niskanen L, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Lakka TA, Niskanen LK, Kumpusalo E, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Mc Intyre RS, Konarski JZ, Misener VL, et al. Bipolar disorder and diabete mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005;17(2):83–93.CrossRefGoogle Scholar
  15. 15.
    Salvi V, D'Ambrosio V, Rosso G, Bogetto F, Maina G. Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci. 2011;65:47–54.PubMedCrossRefGoogle Scholar
  16. 16.
    Miller BJ, Mellor A, Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav Immun. 2013;31:82–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008;20:131–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? 2009;11(6):475–480.Google Scholar
  19. 19.
    Maina G, Salvi V, Vitalucci A, D’Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord. 2008;110(1–2):149–55.PubMedCrossRefGoogle Scholar
  20. 20.
    Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007;68(6):917–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Johannessen L, Strudsholm U, Foldager L, Munk-Jørgensen P. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord. 2006;95:13–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Angst F, Stassenm HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow up of 34–38 years. J Affect Disord. 2002;68:167–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Perris C, d'Ellia G. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand. 1996;164:172–89.Google Scholar
  24. 24.
    Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry. 1980;37(9):979–83.PubMedCrossRefGoogle Scholar
  25. 25.
    • Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12(6):638–46. Good topic for autoimmunity in bipolar disorder with interesting data.PubMedCrossRefGoogle Scholar
  26. 26.
    Vonk R, Van der Schot AC, Kahn RS, et al. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry. 2007;62(2):135–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Cassidy F, Ahearm E, Carroll BJ. Elevated frequency of diabete mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156(9):1417–20.PubMedGoogle Scholar
  28. 28.
    Kupka RW, Regeer EJ. Bipolar mood disorders. Ned Tijdschr Geneeskd. 2007;151(41):2256–60.PubMedGoogle Scholar
  29. 29.
    Severance EG, Dickerson FB, Halling M, et al. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res. 2010;118(1–3):240–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 2009;48:111–36.PubMedCrossRefGoogle Scholar
  31. 31.
    Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med. 2006;119(2):166.e17–28.CrossRefGoogle Scholar
  32. 32.
    Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86.PubMedCrossRefGoogle Scholar
  33. 33.
    Pasco JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry. 2010;197:372–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Wadee AA, Kuschke RH, Wood LA, et al. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol. 2002;17(4):175–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):370–2.PubMedCrossRefGoogle Scholar
  36. 36.
    Dickerson F, Stallings C, Origoni A, et al. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):952–5.PubMedCrossRefGoogle Scholar
  37. 37.
    De Berardis D, Conti CM, Campanella D, Carano A, et al. Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. Int J Immunopathol Pharmacol. 2008;21(2):319–24.PubMedGoogle Scholar
  38. 38.
    Cunha AB, Andreazza AC, Gomes FA, Frey BN, et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2008;258(5):300–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Tsai SY, Chen KP, Yang YY, et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry. 1999;45(8):989–94.PubMedCrossRefGoogle Scholar
  40. 40.
    Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1–3):91–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596–602.PubMedCrossRefGoogle Scholar
  42. 42.
    O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2–3):263–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Rapaport MH, Guylai L, Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res. 1999;33(4):335–40.PubMedCrossRefGoogle Scholar
  44. 44.
    Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136(1–2):110–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun. 2009;23(8):1079–82.PubMedCrossRefGoogle Scholar
  46. 46.
    Knijff EM, Breunis MN, Kupka RW, et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9(7):743–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Mollace V, Muscoli C, Masini E, et al. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev. 2005;57(2):217–52.PubMedCrossRefGoogle Scholar
  48. 48.
    Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34(4):263–71.PubMedGoogle Scholar
  49. 49.
    Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15(4):384–92.PubMedCrossRefGoogle Scholar
  50. 50.
    Kapczinski F, Dias VV, Kauer-Sant'Anna M, Brietzke E, Vazquez GH, Vieta E, et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1366–71.PubMedCrossRefGoogle Scholar
  51. 51.
    Berk M, Conus P, Lucas N, Hallam K, Malhi GS, Dodd S, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9(7):671–8.PubMedCrossRefGoogle Scholar
  52. 52.
    • Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144(1–2):16–27. doi: 10.1016/j.jad.2012.06.010. A recent meta-analysis to assess the role of cytokines in bipolar disorder.PubMedCrossRefGoogle Scholar
  53. 53.
    Pawelec G, Barnett Y, Forsey R, et al. T cells and aging. Front Biosci. 2002;7:d1056–183.PubMedGoogle Scholar
  54. 54.
    Czerski PM, Rybakowski F, Kapelski P, Rybakowski JK, et al. Association of tumor necrosis factor -308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology. 2008;57(1–2):88–94.PubMedCrossRefGoogle Scholar
  55. 55.
    Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002;20(5 Suppl 27):S1–S13.PubMedGoogle Scholar
  56. 56.
    Hwang JP, Tsai SJ, Hong CJ, et al. Interleukin-1 beta -511C/T genetic polymorphism is associated with age of onset of geriatric depression. Neuromolecular Med. 2009;11(4):322–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Papiol S, Molina V, Desco M, et al. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13). Genes Brain Behav. 2008;7(7):796–801.PubMedCrossRefGoogle Scholar
  58. 58.
    Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 65(4):395–407.Google Scholar
  59. 59.
    Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: genes involved and possible mechanisms. Transpl Immunol. 2005;14(3–4):175–82.PubMedCrossRefGoogle Scholar
  60. 60.
    Biederman J, Keller M, Lavori P, et al. HLA haplotype A26-B38 in affective disorders: lack of association. Biol Psychiatry. 1987;22(2):221–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Sorokina TT, Evsegneev RA, Levin VI, Semenov GV. Features of the distribution of HLA-antigens among patients with endogenous psychose. Zh Nevropatol Psikhiatr Im S S Korsakova. 1987;87(6):885–8.PubMedGoogle Scholar
  62. 62.
    • Debnath M, Busson M, Jamain S, et al. The HLA-G low expressor genotype is associated with protection against bipolar disorder. Hum Immunol. 2013;74(5):593–7. Recent data for the implication of the HLAG in bipolar disorder.PubMedCrossRefGoogle Scholar
  63. 63.
    Biederman J, Keller M, Lavori P, Harmatz J, Knee D, Dubey D, et al. HLA haplotype A26-B38 in affective disorders: lack of association. Biol Psychiatry. 1987;22(2):221–4.PubMedCrossRefGoogle Scholar
  64. 64.
    Bozikas VP, Anagnostouli MC, Petrikis P, et al. Familial bipolar disorder and multiple sclerosis: a three-generation HLA family study. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(5):835–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Kaminsky Z, Tochigi M, Jia P, et al. A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder. Mol Psychiatry. 2012;17(7):728–40. doi: 10.1038/mp.2011.64.PubMedCrossRefGoogle Scholar
  66. 66.
    Griffiths DJ. Endogenous retroviruses in the human genome sequence. Genome Biol. 2001;2(6):reviews 1017.CrossRefGoogle Scholar
  67. 67.
    Venter A. New protein blocks HIV. Trends Microbiol. 2001;9(3):110.PubMedCrossRefGoogle Scholar
  68. 68.
    Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein–Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity. 2001;15(4):579–89.PubMedCrossRefGoogle Scholar
  69. 69.
    • Hamdani N, Daban-Huard C, Lajnef M, et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 2013;148(2–3):444–8. Recent data presenting the link between infectious agents and bipolar disorder.PubMedCrossRefGoogle Scholar
  70. 70.
    Frank O, Giehl M, Zheng C, Hehlmann R, Leib-Mosch C, Seifarth W. Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorder. J Virol. 2005;79(17):10890–901.PubMedCrossRefGoogle Scholar
  71. 71.
    Weis S, Llenos IC, Sabunciyan S, et al. Reduced expression of human endogenous retrovirus (HERV)-W GAG protein in the cingulate gyrus and hippocampus in schizophrenia, bipolar disorder, and depression. J Neural Transm. 2007;114(5):645–55.PubMedCrossRefGoogle Scholar
  72. 72.
    Perron H, Mekaoui L, Bernard C, Veas F, Stefas I, Leboyer M. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. Biol Psychiatry. 2008;64(12):1019–23.PubMedCrossRefGoogle Scholar
  73. 73.
    • Perron H, Hamdani N, Faucard R, et al. Molecular characteristics of Human Endogenous Retrovirus type-W (HERV-W) in schizophrenia and bipolar disorder. Transl Psychiatry. 2012. doi: 10.1038/tp.2012.125. The only study involving the HERV in bipolar disorder.PubMedGoogle Scholar
  74. 74.
    Antony JM, van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, et al. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci. 2004;7(10):1088–95.PubMedCrossRefGoogle Scholar
  75. 75.
    Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157(5):683–94.PubMedCrossRefGoogle Scholar
  76. 76.
    Kronfol Z, LeMay L, Nair M, Kluger M. Electroconvulsive therapy increases plasma levels of interleukin-6. Ann NY Acad Sci. 1990;594:463–5.CrossRefGoogle Scholar
  77. 77.
    Boufidou F, Nikolaou C, Alevizos B, Liappas IA, Christodoulou GN. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord. 2004;82(2):309–13.PubMedCrossRefGoogle Scholar
  78. 78.
    Maes M, Calabrese J, Jayathilake K, Meltzer HY. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res. 1997;71(2):67–76.PubMedCrossRefGoogle Scholar
  79. 79.
    Rapaport MH. Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord. 1994;32(3):149–56.PubMedCrossRefGoogle Scholar
  80. 80.
    Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology. 1997;35(3):123–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Bubak-Satora M, Skowron-Cendrzak A, Kubera M. The effect of lithium chloride treatment on cell-mediated immunity in mice. Folia Biol (Krakow). 1991;39(1–4):21–4.Google Scholar
  82. 82.
    Krause I, Cohen J, Blank M, et al. Distribution of two common idiotypes of anticardiolipin antibodies in sera of patients with primary antiphospholipid syndrome, systemic lupus erythematosus and monoclonal gammopathies. Lupus. 1992;1(2):91–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003;62(3):237–44.PubMedCrossRefGoogle Scholar
  84. 84.
    Vale S, Espejel MA, Dominguez JC. Amantadine in depression. Lancet. 1971;2(7721):437.PubMedCrossRefGoogle Scholar
  85. 85.
    Bode L, Durrwald R, Rantam FA, et al. First isolates of infectious human Borna disease virus from patients with mood disorders. Mol Psychiatry. 1996;1(3):200–12.PubMedGoogle Scholar
  86. 86.
    Dietrich DE, Bode L, Spannhuth CW, et al. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord. 2000;2(1):65–70.PubMedCrossRefGoogle Scholar
  87. 87.
    Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry. 1999;32(2):47–55.PubMedCrossRefGoogle Scholar
  88. 88.
    Muller N, Schwarz MJ, Dehning S, Douhe A, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680–4.PubMedCrossRefGoogle Scholar
  89. 89.
    Casolini P, Catalani A, Zuena AR, Angelucci L. Inhibition of COX-2 reduce the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res. 2002;68(3):337–43.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Nora Hamdani
    • 1
    • 2
    • 3
    • 5
    • 6
    Email author
  • Raphael Doukhan
    • 2
  • Ozlem Kurtlucan
    • 2
  • Ryad Tamouza
    • 4
    • 5
  • Marion Leboyer
    • 1
    • 2
    • 3
    • 5
  1. 1.Universite Paris Est, Faculte de medecineCreteilFrance
  2. 2.AP-HP, Hopital H. Mondor, A. Chenevier, Pole de psychiatrieCreteilFrance
  3. 3.INSERM, U955, Equipe Psychiatrie GenetiqueCreteilFrance
  4. 4.INSERM, U940, Immunologie et Histocompatibilite, Hopital Saint-LouisParisFrance
  5. 5.Fondation FondaMentalCreteilFrance
  6. 6.Pole de Psychiatrie, Hôpital A ChenevierCréteilFrance

Personalised recommendations